CA Cancer J Clin. 2013 Jan;63(1):11 -30. 2 Weick JK, Crowley J, Natale RB, et al. A randomized trial of five cisplatin -containing treatments in patients with metastatic non -small -cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1991;9:1157 -1162. 3 Sandler A et al. Paclitaxel –Carboplatin Alone or with Bevacizumab for Non –Small -Cell Lung Cancer. N Engl J Med 2006; 355:2542 -2550. 4 Mendez M et al. New molecular targeted therapies for advanced non -small -cell lung cancer. J Thorac Dis. 2011; 3(1): 30 –56. 5 Pal S K et al. Targeted Therapies for Non –Small Cell Lung Cancer: An Evolving Landscape. Mol Cancer Ther 2010; 9;1931 –44. 6 Socinski M et al. Treatment of Stage IV Non -small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence -Based Clinical Practice Guidelines. Chest 2013; 143(5)(Suppl):e341S –e368S 7 Peters S et al. Metastatic non -small -cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow -up Annals of Oncology 2012: 23 (Supplement 7): vii56 –vii64. 8 L de Petris et al. Treatment of advanced non -small cell lung cancer. Annals of Oncology 2006; 17 (Supplement 2): ii36 –ii41. 9 Massarelli E et al. A retrospective analysis of the outcome of patients who have received two p rior chemotherapy regimens including platinum and docetaxel for recurrent non -small -cell lung cancer. Lung Cancer 2003;39:55 –61. 10 Asahina H et al. Retrospective analysis of third -line and fourth -line chemotherapy for advanced non - small -cell lung cancer. C lin Lung Cancer 2012;13:39 –43. 11 Ramalingam S & Sandler S. Salvage Therapy for Advanced Non -Small Cell Lung Cancer: Factors Influencing Treatment Selection. The Oncologist 2006;11:655 –665. 12 de Marinis F & Grossi F: Clinical evidence for second - and third -line treatment options in advanced non - small cell lung cancer. Oncologist 2008; 13(Suppl 1): 14 -20. 13 Brenner H et al. Long -term survival expectations of cancer patients in Europe in 2000 -2002. Eur J Cancer 2009; 45:1028 –1041. 14 Gridelli C et al. Treatment of advanced non -small -cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Annals of Oncology (2004); 15: 419 –426. 15 Brundage M et al. Prognostic factors in non -small cell lung cancer: A decade of progress. Chest , 2002; 122:1037 -1057. 16 Topalian S et al. Safety, activity, and immune correlates of anti –PD-1 antibody in cancer. N Engl J Med 2012;366:2443 -54. 17 Morgan DJ, Kreuwel HT, Fleck S, et al. Activation of low avidity CTL specific for a self -epitope results in tumor rejection but not autoimmunity. J Immunol. 1998;160:643 -651. 18 Nigam A, Yacavone RF, Zahurak ML, et al . Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM -CSF-secreting cancer cell vaccines. Int J Oncol. 1998;12: 161-170. 19 Jaffee EM, Abrams R, Cameron J , et al. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM -CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther. 1998;9:1951 -1971. 20 Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525 -531. 21 Kelly JM, Darcy PK, Markby JL , et al . Induction of tumor -specific T cell memory by NK cell -mediated tumor rejection. Nat Immunol. 2002;3:83 -90. 22 Li Y, McGowan P, Hellstrom I, et al. Costimulation of tumor -reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol. 1994;153:421 -428. Heat Biologics, Inc. Investigational Product: V iagenpumatucel -L Protocol HS110 -201 CONFIDENTIAL Version 4.0; 29 -Oct-2014 Page 82 of 84 23 Li Y, Hellstrom KE, Newby SA, et al. Costimulation by CD48 and B7 -1 induces immunity against poorly immuno genic tumors. J Exp Med. 1996;183:639 -644. 24 Chen L, McGowan P, Ashe S, et al. B7-1/CD80 -transduced tumor cells elicit better systemic immunity than wild -type tumor cells admixed with Corynebacterium parvum. Cancer Res. 1994;54:5420 -5423. 25 Johnston JV, Ma lacko AR, Mizuno MT, et al. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I -restricted CD8+ cytolytic T lymphocytes. J Exp Med. 1996;183:791 -800. 26 Yang G, Mizuno LMT, Hellstrom KE, et al. B7-negative versus B7 -positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes. J Immunol. 1997;158:851 -858. 27 Nabel GJ, Chang AE, Nabel EG, et al. Immunotherapy for cancer by direct gene transfer into tum ors. Hum Gene Ther. 1994;5:57 -77. 28 Nabel GJ, Gordon D, Bishop DK, et al . Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA -liposome complexes: direct gene transfer for treatment of hum an cancer. Proc Natl Acad Sci U S A.